Von Hippel-Lindau tumor suppressor protein transforms human neuroblastoma cells into functional neuron-like cells.

Von Hippel-Lindau (VHL) tumor suppressor protein is expressed in neurons of the central nervous system and plays an important role during the neuronal differentiation of central nervous system progenitor cells. To elucidate the neuronal differentiating potential of VHL protein in neuroblastoma cells, we overexpressed or inhibited VHL protein in human neuroblastoma cells (SY-SH5Y), and examined the morphological change, expressions of neuronal markers, and electrophysiological functions. Here we show that with VHL gene transduction SY-SH5Y cells stably expressing the VHL protein had neurite-like processes with varicosities, showed the distinct expression of the neuronal markers neuropeptide Y and neurofilament 200, acquired regulated neurosecretion competence in response to depolarizing and cholinergic stimuli, and had large voltage-gated fast sodium currents and delayed rectifier potassium (Kv) currents compatible with those of functional neurons. In addition, they displayed inactivated ether-á-go-go potassium channels related to the promotion of the cell cycle and to the termination of differentiation. Also, by treatment with retinoic acid, they rapidly underwent cell death related to apoptosis. These findings suggest that the induction of neuronal function by VHL protein is associated with down-regulation of the cell cycle. In contrast, the inhibition of endogenous expression of VHL protein with antisense-orientated VHL gene transduction reduced such neuronal properties inherent to these cells, including the capacity for activation of ether-á-go-go channels. In conclusion, VHL protein has a neuronal differentiating potential to transform neuroblastoma cells into functional neuron-like cells. Our finding of the neuronal differentiation of neuroblastoma cells under the control of the VHL gene may contribute to the development of clinical techniques for neuronal regeneration in the case of intractable neuronal diseases and for differentiation therapy against neuroblastomas.

[1]  C. Reynolds,et al.  Retinoid therapy of childhood cancer. , 2001, Hematology/oncology clinics of North America.

[2]  L. Larsson,et al.  Interferon‐γ cooperates with retinoic acid and phorbol ester to induce differentiation and growth inhibition of human neuroblastoma cells , 2001, International journal of cancer.

[3]  John S. Beech,et al.  Resolution of Stroke Deficits Following Contralateral Grafts of Conditionally Immortal Neuroepithelial Stem Cells , 2001, Stroke.

[4]  D. Mukhopadhyay,et al.  The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. , 2001, Cancer research.

[5]  Stephen Lee,et al.  Role of Exon 2-encoded β-Domain of the von Hippel-Lindau Tumor Suppressor Protein* , 2001, The Journal of Biological Chemistry.

[6]  B. Urban,et al.  Stereospecific interaction of ketamine with nicotinic acetylcholine receptors in human sympathetic ganglion-like SH-SY5Y cells. , 2000, Anesthesiology.

[7]  T. Shuin,et al.  Role of the von Hippel-Lindau tumor suppressor protein during neuronal differentiation. , 2000, Cancer research.

[8]  R. Klausner,et al.  Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  L. Pardo,et al.  Oncogenic potential of EAG K+ channels , 1999, The EMBO journal.

[10]  M. Gstaiger,et al.  The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. , 1999, Genes & development.

[11]  S. Soker,et al.  Neuropilin-1 Mediates Collapsin-1/Semaphorin III Inhibition of Endothelial Cell Motility , 1999, The Journal of cell biology.

[12]  B. Zbar,et al.  Expression of von Hippel–Lindau Protein in Normal and Pathological Human Tissues , 1999, The Histochemical Journal.

[13]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[14]  J. Meldolesi,et al.  Neurosecretion Competence, an Independently Regulated Trait of the Neurosecretory Cell Phenotype* , 1998, The Journal of Biological Chemistry.

[15]  L. Pardo,et al.  Cell Cycle–related Changes in the Conducting Properties of r-eag K+ Channels , 1998, The Journal of cell biology.

[16]  W. Kaelin,et al.  von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. , 1998, Cancer research.

[17]  R. Burk,et al.  A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  R. Lovell-Badge,et al.  A role for SOX1 in neural determination. , 1998, Development.

[19]  S. Påhlman,et al.  Activated Transcription of the Human Neuropeptide Y Gene in Differentiating SH‐SY5Y Neuroblastoma Cells Is Dependent on Transcription Factors AP‐1, AP‐2α, and NGFI , 1998, Journal of neurochemistry.

[20]  S. Heinemann,et al.  Characterization of an eag‐like potassium channel in human neuroblastoma cells , 1998, The Journal of physiology.

[21]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[22]  K. Prasad,et al.  Improvement of neurological deficits in 6-hydroxydopamine-lesioned rats after transplantation with allogeneic simian virus 40 large tumor antigen gene-induced immortalized dopamine cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Klausner,et al.  The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Trojanowski,et al.  Transplantation of Cryopreserved Human Embryonal Carcinoma-Derived Neurons (NT2N Cells) Promotes Functional Recovery in Ischemic Rats , 1998, Experimental Neurology.

[25]  M. Turman,et al.  Somatostatin expression in human renal cortex and mesangial cells , 1997, Regulatory Peptides.

[26]  J. Kukkonen,et al.  Locatization of Voltaae‐sensitive Ca2+ Fluxes and Neuropeptide Y Immunoreactivity to Varicosities in SH‐SY5Y Human Neuroblastoma Cells Differentiated by Treatment with the Protein Kinase Inhibitor Staurosporine , 1997, The European journal of neuroscience.

[27]  V. Taglietti,et al.  Functional changes in sodium conductances in the human neuroblastoma cell line SH-SY5Y during in vitro differentiation. , 1996, Journal of neurophysiology.

[28]  Y. Miyagi,et al.  VON HIPPEL–LINDAU TUMOUR SUPPRESSOR GENE. LOCALIZATION OF EXPRESSION BY IN SITU HYBRIDIZATION , 1996, The Journal of pathology.

[29]  W. Kaelin,et al.  Expression pattern of the von Hippel-Lindau protein in human tissues. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[30]  A. Kibel,et al.  Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.

[31]  R. Klausner,et al.  Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Weintraub,et al.  Conversion of Xenopus ectoderm into neurons by NeuroD, a basic helix-loop-helix protein. , 1995, Science.

[33]  B. Seizinger,et al.  Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: implications for the potential organization of the human von Hippel-Lindau disease gene. , 1995, Cancer research.

[34]  T. Shuin,et al.  Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. , 1994, Cancer research.

[35]  Y Kubota,et al.  Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. , 1994, Cancer research.

[36]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[37]  T. Gotow,et al.  Phosphorylation of neurofilament H subunit as related to arrangement of neurofilaments , 1994, Journal of neuroscience research.

[38]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[39]  C. Markham,et al.  Transplantation of Human Neuroblastoma Cells, Catecholaminergic and Non-Catecholaminergic: Effects on Rotational Behavoir in Parkinson's Rat Model , 1992, Journal of neural transplantation & plasticity.

[40]  K. Åkerman,et al.  Staurosporine induces a neuronal phenotype in SH‐SY5Y human neuroblastoma cells that resembles that induced by the phorbol ester 12‐O‐tetradecanoyl phorbol‐13 acetate TPA) , 1992, FEBS letters.

[41]  David J. Anderson,et al.  Two rat homologues of Drosophila achaete-scute specifically expressed in neuronal precursors , 1990, Nature.

[42]  M. Shani,et al.  The nucleotide sequence of the rat cytoplasmic β–actin gene , 1983 .

[43]  G. Shaw,et al.  Differential expression of neurofilament triplet proteins in brain development , 1982, Nature.

[44]  B. Hallberg,et al.  Differences in early and late responses between neurotrophin-stimulated trkA- and trkC-transfected SH-SY5Y neuroblastoma cells. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[45]  J. Trojanowski,et al.  Neurobiology of human neurons (NT2N) grafted into mouse spinal cord: implications for improving therapy of spinal cord injury. , 2000, Progress in brain research.

[46]  V. Taglietti,et al.  Functional changes in potassium conductances of the human neuroblastoma cell line SH-SY5Y during in vitro differentiation. , 1998, Journal of neurophysiology.

[47]  M. Shani,et al.  The nucleotide sequence of the rat cytoplasmic beta-actin gene. , 1983, Nucleic acids research.